246 related articles for article (PubMed ID: 24368231)
1. Metabolomics in polycystic ovary syndrome.
Murri M; Insenser M; Escobar-Morreale HF
Clin Chim Acta; 2014 Feb; 429():181-8. PubMed ID: 24368231
[TBL] [Abstract][Full Text] [Related]
2. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome.
Chang AY; Lalia AZ; Jenkins GD; Dutta T; Carter RE; Singh RJ; Nair KS
Metabolism; 2017 Jun; 71():52-63. PubMed ID: 28521878
[TBL] [Abstract][Full Text] [Related]
3. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance.
Chen YX; Zhang XJ; Huang J; Zhou SJ; Liu F; Jiang LL; Chen M; Wan JB; Yang DZ
J Pharm Biomed Anal; 2016 Mar; 121():141-150. PubMed ID: 26808063
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive urinary metabolomics reveals metabolic profiling of polycystic ovary syndrome and its subtypes.
Zhou W; Hong Y; Yin A; Liu S; Chen M; Lv X; Nie X; Tan N; Zhang Z
J Pharm Biomed Anal; 2020 Jun; 185():113262. PubMed ID: 32222648
[TBL] [Abstract][Full Text] [Related]
5. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.
Amato MC; Guarnotta V; Forti D; Donatelli M; Dolcimascolo S; Giordano C
Hum Reprod; 2013 Jul; 28(7):1919-28. PubMed ID: 23592224
[TBL] [Abstract][Full Text] [Related]
6. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS.
Escobar-Morreale HF; Samino S; Insenser M; Vinaixa M; Luque-Ramírez M; Lasunción MA; Correig X
Clin Chem; 2012 Jun; 58(6):999-1009. PubMed ID: 22427353
[TBL] [Abstract][Full Text] [Related]
7. Abdominal adiposity and the polycystic ovary syndrome.
Escobar-Morreale HF; San Millán JL
Trends Endocrinol Metab; 2007 Sep; 18(7):266-72. PubMed ID: 17693095
[TBL] [Abstract][Full Text] [Related]
8. Metabolomic Insight into Polycystic Ovary Syndrome-An Overview.
Rajska A; Buszewska-Forajta M; Rachoń D; Markuszewski MJ
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659951
[TBL] [Abstract][Full Text] [Related]
9. Polycystic ovary syndrome in the Indian Subcontinent.
Allahbadia GN; Merchant R
Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
[TBL] [Abstract][Full Text] [Related]
10. Emerging Metabolomics Biomarkers of Polycystic Ovarian Syndrome; Targeting the Master Metabolic Disrupters for Diagnosis and Treatment.
Omabe M; Elom S; Omabe KN
Endocr Metab Immune Disord Drug Targets; 2018; 18(3):221-229. PubMed ID: 29359679
[TBL] [Abstract][Full Text] [Related]
11. Polycystic ovary syndrome.
Nandi A; Chen Z; Patel R; Poretsky L
Endocrinol Metab Clin North Am; 2014 Mar; 43(1):123-47. PubMed ID: 24582095
[TBL] [Abstract][Full Text] [Related]
12. Metabolic alterations associated with polycystic ovary syndrome: A UPLC Q-Exactive based metabolomic study.
Chen X; Lu T; Wang X; Sun X; Zhang J; Zhou K; Ji X; Sun R; Wang X; Chen M; Ling X
Clin Chim Acta; 2020 Mar; 502():280-286. PubMed ID: 31758934
[TBL] [Abstract][Full Text] [Related]
13. Obesity and the polycystic ovary syndrome.
Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
[TBL] [Abstract][Full Text] [Related]
14. Lipidomics biomarkers in women with polycystic ovary syndrome (PCOS) using ultra-high performance liquid chromatography-quadrupole time of flight electrospray in a positive ionization mode mass spectrometry.
Vonica CL; Ilie IR; Socaciu C; Moraru C; Georgescu B; Farcaş A; Roman G; Mureşan AA; Georgescu CE
Scand J Clin Lab Invest; 2019 Oct; 79(6):437-442. PubMed ID: 31462125
[TBL] [Abstract][Full Text] [Related]
15. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome.
Toscani M; Migliavacca R; Sisson de Castro JA; Spritzer PM
Metabolism; 2007 Jul; 56(7):992-7. PubMed ID: 17570263
[TBL] [Abstract][Full Text] [Related]
16. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
Graff SK; Mário FM; Alves BC; Spritzer PM
Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the understanding and management of polycystic ovary syndrome.
Rocha AL; Oliveira FR; Azevedo RC; Silva VA; Peres TM; Candido AL; Gomes KB; Reis FM
F1000Res; 2019; 8():. PubMed ID: 31069057
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Syndrome in Polycystic Ovary Syndrome.
Pasquali R
Front Horm Res; 2018; 49():114-130. PubMed ID: 29894990
[TBL] [Abstract][Full Text] [Related]
20. Obesity and polycystic ovary syndrome.
Barber TM; McCarthy MI; Wass JA; Franks S
Clin Endocrinol (Oxf); 2006 Aug; 65(2):137-45. PubMed ID: 16886951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
